LSE:BSFA
BSF Enterprise PLC
Investment Banking and Brokerage Services
1.75p 0p 0.00% (as of close on 29/5/26)
| Market cap (m) | £2.9 |
| Enterprise value (m) | £2.8 |
BSF Enterprise PLC is a United Kingdom-based biotech company. The Company is focused on developing biotechnological solutions using cell-based tissue engineering to help generate cultured meat, lab-grown leather, as well as human corneas, collagen growth and skin substitutes. The Company operates through its wholly owned subsidiary, 3D Bio-Tissues Limited (3DBT), which is a clinical and cellular agriculture company engaged in producing human corneas that could help restore vision to millions of people.
Last Updated: 28/05/2026
BSF Enterprise reported milestones across subsidiaries. Lab-Grown Leather unveiled a -T-rex leather- handbag made using synthetic dinosaur DNA, with an auction scheduled for 11 June in Paris. Kerato began phase-one veterinary trials funded by the Canadian government and targets signing distribution deals in Q4 2026; applications for human trials are planned for 2026-2027.
For Lab-Grown Leather and Kerato, BSF is evaluating subsidiary-level financing options, including possible spin-outs. 3D Bio-Tissues launched its CytoBoost Revive product, has a commercial pipeline estimated at GBP500,000, and plans new partnerships in the second and third quarters. The company said 2026 marks a shift of subsidiaries from research and development toward commercialisation.
